Ocular Therapeutix Inc. (OCUL)
OCUL trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1393434/000110465926010664/0001104659-26-010664-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | OCUL on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2014 |
| SEC CIK | 0001393434 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $52.0M |
| Net income | -$265.9M |
| Operating income | -$270.0M |
| Net margin | -511.9% |
| Operating margin | -519.8% |
| Revenue growth | -18.5% |
| Cash | $737.1M |
| Total assets | $808.1M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 25.5× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-09 |
| Cash and burn | $530.6M cash; operating cash flow -$63.3M a quarter. | Report 2026-09-30 |
| Shares outstanding | 220,022,840 (2026-11-06); 213,047,472 a year earlier; 79,418,626 three years earlier. | Cover page 2026-11-06 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | PricewaterhouseCoopers LLP, Boston, Massachusetts, United States | PCAOB Form AP 2026-02-18 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $461K, sold $3.4M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $12.9M | -$94.8M | -$65.6M | $530.6M | No debt tags | $50.4M | 10-Q 2026-11-09 |
| Q2 2026 2026-06-30 | $13.5M | -$78.8M | -$67.3M | $598.6M | No debt tags | $52.1M | 10-Q 2026-08-03 |
| Q1 2026 2026-03-31 | $10.8M | -$88.6M | -$66.0M | $666.7M | No debt tags | $52.0M | 10-Q 2026-05-05 |
| Q4 2025 2025-12-31 | $13.3M | -$64.7M | -$54.2M | $737.1M | No debt tags | $52.0M | 10-K 2026-02-05 |
| Q3 2025 2025-09-30 | $14.5M | -$69.4M | -$50.7M | $344.8M | No debt tags | $55.8M | 10-Q 2026-11-09 |
| Q2 2025 2025-06-30 | $13.5M | -$67.8M | -$55.2M | $391.1M | No debt tags | $56.7M | 10-Q 2026-08-03 |
| Q1 2025 2025-03-31 | $10.7M | -$64.1M | -$44.7M | $349.7M | No debt tags | $59.6M | 10-Q 2026-05-05 |
| Q4 2024 2024-12-31 | $17.1M | -$48.4M | -$39.4M | $392.1M | No debt tags | $63.7M | 10-K 2026-02-05 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2025-09-30 |
| Latest annual report | 10-K | 2026-02-05 |
| Latest quarterly / interim | 10-Q | 2026-11-09 |
| Latest current report FORM 8-K | 8-K | 2026-11-09 |
| Latest proxy | DEFA14A | 2026-04-30 |
Source: SEC EDGAR submissions feed, 872 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -5.8% |
| 1 month | -14.2% |
| 3 months | -38.5% |
| Year to date | -48.8% |
| 1 year | -44.5% |
| From 52-week high | -61.5% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| AVLN | Avalyn Pharma Inc. | $29.76 | -1.72% | $1.3B |
| GPCR | Structure Therapeutics Inc. | $18.57 | -7.15% | $1.3B |
| INVA | Innoviva Inc. | $18.49 | -2.84% | $1.3B |
| GENB | Generate Biomedicines Inc. | $10.49 | -13.09% | $1.4B |
| NUVB | Nuvation Bio Inc. | $3.84 | -3.76% | $1.4B |
| MLYS | Mineralys Therapeutics Inc. | $14.53 | -5.22% | $1.3B |
| ANAB | AnaptysBio Inc. | $45.73 | -1.12% | $1.4B |
| GHRS | GH Research PLC | $18.75 | -1.83% | $1.3B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier